Garadacimab-Gxii 200mg/1.2ml Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 200mg/1.2ml

Reference Brands: Andembry (USA/EU)

Category: Critical Care

Garadacimab-gxii, marketed as Andembry, is a monoclonal antibody used for the prevention of hereditary angioedema (HAE) attacks in adolescents and adults. It works by inhibiting activated coagulation factor XIIa (FXIIa), which reduces the production of bradykinin, a substance that causes swelling in HAE attacks. Administered once monthly as a subcutaneous injection, it helps patients manage and prevent recurrent episodes of HAE, improving quality of life.

Product Description:

Garadacimab is a monoclonal antibody against activated factor XII, the first protein in the contact activation pathway. In hereditary angioedema, uncontrolled activation of that pathway generates bradykinin, which makes blood vessels leak and produces the swelling attacks. Blocking factor XIIa stops the cascade at its start, upstream of kallikrein and bradykinin.

It is used to prevent attacks in patients aged twelve and over, given as a subcutaneous injection once a month after a loading dose — the only long-term preventive in this condition with monthly dosing for all patients from the start. In its pivotal trial it reduced attack rates by around ninety percent, and a large share of patients had no attacks at all during treatment. It is a preventive, not a rescue treatment; patients still need an on-demand medicine for breakthrough attacks. Injection site reactions and upper respiratory infections are the common adverse effects; no signal of abnormal bleeding has emerged, consistent with factor XII having little role in normal haemostasis.

Sourcing notes. Originator biologic, approved in the EU and US in 2025, on patent with no biosimilar. Cold chain, self-administered after training. Supply is through authorised distribution, usually via specialist immunology centres.